Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959463 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
A Phase 1 study of Pleural Malignant Mesothelioma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02959463 is a Phase 1 study of Pleural Malignant Mesothelioma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants, below the 61-participant average among 4 other Pleural Malignant Mesothelioma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02959463, a Phase 1 study of Pleural Malignant Mesothelioma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma. Radiation therapy uses high energy radiation to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after radiation therapy may kill more tumor cells.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
- RADIATION Palliative Radiation Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02959463
The ClinicalTrials.gov registry entry for NCT02959463 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 4 other Pleural Malignant Mesothelioma trials with a reported enrollment target (61% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pleural Malignant Mesothelioma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02959463 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02959463 about?
NCT02959463 is a clinical study titled "Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma". This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma. Radiation therapy uses high energy radiation to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembr...
What is the current status of trial NCT02959463?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-05-01. Estimated completion is 2028-12-31.
What conditions does trial NCT02959463 study?
This clinical trial studies the following conditions: Pleural Malignant Mesothelioma.
What interventions are being tested in trial NCT02959463?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION), Palliative Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02959463?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02959463 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleural Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab in Treating Patients With Malignant Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
-
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.